SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Advanced Environmental Petroleum (AEPP)

AEPP RSS Feed
Add AEPP Price Alert      Hide Sticky   Hide Intro
Moderator: BottomWatcher , Rat Fink, fuzzymcilwoods, BillyParks, ninersax, BLight1911
Search This Board: 
Last Post: 8/20/2017 10:34:17 PM - Followers: 163 - Board type: Free - Posts Today: 0

 

BIOTECH Merger in Action


April 24 Interview with CEO Michael Redman
 
 


On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company.



Verified Company Profile  4/10/2017
Email: mredman@oncolixbio.com
 

AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder

https://www.sec.gov/Archives/edgar/data/1574061/000147793217001787/aepp_sc13d.htm
https://www.sec.gov/Archives/edgar/data/1584137/000147793217001656/aepp_8k.htm



AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc. 


Initial agreement was made on March 7, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74041605

http://ih.advfn.com/p.php?pid=nmona&article=74093500

Merger expected to be finalized on or around April 3, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74157198

AEPP UPDATE:

Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO

Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.

 
AEPP Security Details
Share Structure
  Market Value1 $3,571,704 a/o Apr 07, 2017
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 33,311,633 a/o Apr 06, 2017
  Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 101 a/o Apr 06, 2017

 


Zero outstanding debt

"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
http://ih.advfn.com/p.php?pid=nmona&article=74093500 

April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).

Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.


 

Who is Oncolix, Inc.?

https://oncolixbio.com

April 2017 Company Presentation:
https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN

https://www.youtube.com/watch?v=Ox6n1HH8v_0&feature=youtu.be
 

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.   

The FDA has also approved the designation of 
Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. 

Prolanta is currently in FDA clinical trials phase 1. 
https://clinicaltrials.gov/ct2/show/NCT02534922

Oncolix received Orphan Drug Status for their developmental drug Prolanta.
http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html

8 U.S. Patents have been awarded in the development of Prolanta
http://oncolixbio.com/patents.html

 

PATENTS

The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.

Patent Number Issue Date Issued To Title
US 7,115,556 03 OCT 2006 Oncolix Use of Anti-Prolactin Agents to Treat Proliferative Conditions
US 7,201,905 10 APR 2007 Oncolix Bi-Functional Cancer Treatment Agents
US 7,339,027

US 8,304,381
4 MAR 2008

6 NOV 2012
Oncolix Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,632,809 15 DEC 2009 Oncolix Multimeric Ligands with Enhanced Stability
US 8,648,046

US 8,754,035
11 FEB 2014

17 JUN 2014
Oncolix Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
US 8,754,031 17 JUN 2014 Oncolix Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway

Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer.  Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.

 

 

The Oncolix Team

Management

\

\

Board Members

\

\

\

Company Advisors

\

\

\



 





 


https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12149068

AEPP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AEPP News: Quarterly Report (10-q) 08/18/2017 05:09:11 PM
AEPP News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/14/2017 12:12:18 PM
AEPP News: Initial Statement of Beneficial Ownership (3) 08/11/2017 02:25:22 PM
AEPP News: Initial Statement of Beneficial Ownership (3) 08/11/2017 01:17:26 PM
AEPP News: Small Company Offering and Sale of Securities Without Registration (d) 08/10/2017 01:50:29 PM
PostSubject
#10441  Sticky Note PAGE 18 OF AEPP 10Q MENTIONS "$8 MILLION_FINANCING_LISTING_TO_NASDAQ_OR_NYSE"!!! Rat Fink 08/20/17 03:42:13 PM
#8084  Sticky Note AEPP/Oncolix summary. reaper247 07/20/17 06:32:22 PM
#10445   Based on charts, imo, this should go up tmcfo 08/20/17 08:51:43 PM
#10444   The $AEPP rocket getting fueled up. More CatfishHunter 08/20/17 07:24:55 PM
#10443   Hey Pinky4 hope all is well. I've been ammobox 08/20/17 07:17:49 PM
#10442   Man they have a good bit of financing Pinky4 08/20/17 06:12:07 PM
#10441   PAGE 18 OF AEPP 10Q MENTIONS "$8 MILLION_FINANCING_LISTING_TO_NASDAQ_OR_NYSE"!!! Rat Fink 08/20/17 03:42:13 PM
#10440   Anyone has comments on the 10Q? Anything new? tmcfo 08/20/17 01:18:59 PM
#10439   Indeed Eltp 08/20/17 12:46:25 PM
#10438   That would be great. Filings finally over.. Redman BottomWatcher 08/20/17 12:45:39 PM
#10437   I think Redman is getting ready to blast Eltp 08/20/17 12:38:44 PM
#10436   There would be big catalyst along the way.. BottomWatcher 08/20/17 12:10:57 PM
#10435   Yes, very exiting play! The wait is tmcfo 08/20/17 12:09:18 PM
#10434   This will be on multiple dollars Jan 2018 BottomWatcher 08/20/17 12:03:17 PM
#10433   Let the story unfold....i am in it for tmcfo 08/20/17 11:59:51 AM
#10432   This is possible.. REDMAN mentioned uplist to NASDAQ/NYSE BottomWatcher 08/20/17 11:55:42 AM
#10431   http://www.xconomy.com/texas/2017/08/07/houston-biotech-oncolix-announces-revers BottomWatcher 08/20/17 11:49:54 AM
#10430   The data will be presented in Jp Morgan Eltp 08/20/17 11:48:07 AM
#10429   In a short four months or sooner, we tmcfo 08/20/17 11:45:16 AM
#10428   We are the early birds in finding this Eltp 08/20/17 11:39:09 AM
#10427   Yes, indeed..the opportunity is there and we know tmcfo 08/20/17 11:36:37 AM
#10426   It will be amazing for us to see Eltp 08/20/17 11:34:03 AM
#10425   Yes, absolutely. Science dictates market potential tmcfo 08/20/17 11:32:11 AM
#10424   Lots of big pharmas are hunting for that Eltp 08/20/17 11:32:05 AM
#10423   Exactly, it's all based on potential nothing to Eltp 08/20/17 11:28:32 AM
#10422   If they believe that Prolanta science is unique tmcfo 08/20/17 11:27:02 AM
#10421   I was thinking the same thing knowing that Eltp 08/20/17 11:23:01 AM
#10420   I won't be surpriced if Oncolix has tmcfo 08/20/17 10:22:09 AM
#10419   Name change coming very soon! steadyhand 08/20/17 09:25:14 AM
#10418   Good Morning ONCOLIX!!! arbytrader 08/20/17 08:10:12 AM
#10417   Pure nonsense... wrong board. BottomWatcher 08/19/17 07:49:34 PM
#10416   AEPP 3 month chart refuting any .01 nonsense: zen222 08/19/17 07:36:37 PM
#10415   GREAT 30% 2ND HALF-DAY RISE!!! I GUESS_SOMEONE_LIKED_AEPPs_RELEASED_10Q!!! Rat Fink 08/19/17 07:03:03 PM
#10414   You always add a value to the board, Eltp 08/19/17 07:01:29 PM
#10413   False, AEPP/Oncolix is an absolute steal at these prices. BLight1911 08/19/17 07:01:02 PM
#10412   Wrong board again. AEPP getting ready to break CatfishHunter 08/19/17 07:00:14 PM
#10411   Not a chance in hell. Better odds of dabullishbear 08/19/17 06:56:28 PM
#10410   This scam is going to .01 after it Airstock 08/19/17 06:48:57 PM
#10409   Friday was fantastic. I can't wait for the BLight1911 08/19/17 05:32:15 PM
#10408   Well well well. Turns out the longs were steadyhand 08/19/17 05:23:24 PM
#10407   More like great for the first time. dabullishbear 08/19/17 04:09:14 PM
#10406   Michael Redman making AEPP great again!!! arbytrader 08/19/17 03:18:31 PM
#10405   Absolutely, things are not going dark after ticker Eltp 08/19/17 09:59:24 AM
#10404   There are always things happening in between microcaptrdr24 08/19/17 09:41:11 AM
#10392   I'm hanging around lol Eltp 08/18/17 08:52:16 PM
#10391   Wow MACD going up on positive bullish territory BottomWatcher 08/18/17 08:35:42 PM
#10389   So does barchart with current and direction strenght... tmcfo 08/18/17 08:33:42 PM
#10387   AEPP chart showing marked improvement with bullish crossovers: zen222 08/18/17 08:25:08 PM
#10385   I was 15 years old lol Pinky4 08/18/17 08:00:50 PM
#10384   Wow now that I did not know!!!! Pinky4 08/18/17 07:59:05 PM
#10383   Those last financing pr' s that came out Pinky4 08/18/17 07:57:11 PM
#10382   Here is a publication dating back to November dabullishbear 08/18/17 07:46:22 PM
PostSubject